极光官网加速器官网

For diff-in-diff, the treatment status of a unit can vary over time. However, we only permit two treatment histories: never treated (the control group) and treated in the post-intervention period only (the treated group). Thus, we will use landeng破解版安卓版5.0.1 and \(A=1\) to represent the control and treated groups, with the understanding that the treated group only receives treatment whenever \(t > T_0\) (see notation).

Every unit has two potential outcomes, but we only observe one — the one corresponding to their actual treatment status. The consistency assumption links the potential outcomes \(Y^a(t)\) at time \(t\) with treatment lanter专业破解版百度云 to the observed outcomes \(Y(t)\).

Consistency Assumption
\[ Y(t) = (1 - A) \cdot Y^0(t) + A \cdot Y^1(t) \]

If a unit is treated \((A=1)\), then the observed outcome is the potential outcome with treatment \(Y(t) = Y^1(t)\) and the potential outcome with no treatment \(Y^0(t)\) is unobserved. If a unit is not treated \((A=0)\), then \(Y(t) = Y^0(t)\) and landeng官网专业破解版 is unobserved.

Arrow of time \[ Y(t) = Y^0(t) = Y^1(t),\; \mbox{for}\ t \leq T_0 \]

软件实验室-去广告绿色破解软件分享博客 - Android:去广告安卓软件下载，绿色软件下载 landeng 5.0.2 专业破解版 【landeng】破解专业版应用仅限用于学习和研究目的，破解不制造不存储任何有关翻山的通信与数据，不参与任何landeng官方开发，不记录任何用 …

A second key assumption we make is that the change in outcomes from pre- to post-intervention in the control group is a good proxy for the counterfactual change in untreated potential outcomes in the treated group. When we observe the treated and control units only once before treatment \((t=1)\) and once after treatment lan灯破解版安卓版, we write this as:

Counterfactual Assumption (1) \[\begin{align*} \mathbb{E}\left[Y^0(2) - Y^0(1) \mid A = 1\right] = \\ \nonumber \mathbb{E}\left[Y^0(2) - Y^0(1) \mid A = 0\right] \end{align*}\]

This is an assumption — not something we can test — because it involves unobserved counterfactual outcomes, namely landeng破解版安卓版最新 for \(A = 1\).

In the shiny app embedded below, we can see what the counterfactual assumption does and how we calculate the ATT under our assumptions. The solid black lines represent the observed data. When we click the “Impute Counterfactual from Control to Treated” button, the slope of the line of the control group is imputed to the treated group (dashed line). Finally, clicking the “Show diff-in-diff effect button” reveals how we calculate the average effect of treatment on the treated (ATT).

Traditionally, this assumption is called the parallel trends assumption, but as we will soon see, that term can be ambiguous.

landeng破解版安卓版5.0.1

Lastly, we make a positivity assumption. With the positivity assumption, we assume that treatment is not determinant for specific values of landeng破解版安卓版5.0.1. Thus, for any \(X = x\), the probability of being treated (or untreated) lies between 0 and 1, not inclusive.

Positivity Assumption \[\begin{equation*} 0 < P(A = 1 | X) < 1 \; \text{ for all } X. \end{equation*}\]

We will invoke the positivity assumption explicitly when we discuss semiparametric and nonparametric estimators.

极光官网加速器官网

Using the assumptions above, we can re-write the the target estimand (which involved unobserved counterfactuals) in a form that depends only on observed outcomes. This process is called “identification”.

For diff-in-diff, identification begins with the ATT, applies the Counterfactual Assumption (1) and the Consistency Assumption, and ends with the familiar diff-in-diff estimator.

The result is the familiar diff-in-diff estimator

\[\begin{align*} ATT &\equiv \mathbb{E}\left[Y^1(2) - Y^0(2) \mid A = 1\right] \\ &= \lbrace \mathbb{E}\left[Y(2) \mid A = 1\right] - \mathbb{E}\left[Y(1) \mid A = 1\right] \rbrace - \\ & \ \ \ \ \ \ \lbrace \mathbb{E}\left[Y(2) \mid A = 0\right] - \mathbb{E}\left[Y(1) \mid A = 0\right] \rbrace \end{align*}\]

For a straightforward estimate of the ATT, we could simply plug in the sample averages for the four expectations on the right-hand side:

1. The post-intervention average of the treated group for \(\mathbb{E}\left[Y(2) \mid A = 1\right]\);
2. The pre-intervention average of the treated group for \(\mathbb{E}\left[Y(1) \mid A = 1\right]\);
   
3. The post-intervention average of the control group for \(\mathbb{E}\left[Y(2) \mid A = 0\right]\);
   
4. The pre-intervention average of the control group for \(\mathbb{E}\left[Y(1) \mid A = 0\right]\).

Finding the standard error for this estimator is a little more complex, but we could estimate it by bootstrapping, for example.

Sometimes the counterfactual assumption may hold only after conditioning on some observed covariates, and the identification becomes more complex. More on this in the Confounding section.

极光官网加速器官网

We can calculate the ATT at any of the post-treatment time points

Time-varying ATT
Individual time points
For some \(t > T_0\), \[\begin{equation*} ATT(t) \equiv \mathbb{E}\left[Y^1(t) - Y^0(t) \mid A = 1\right] \end{equation*}\]

or we can compute the average ATT across the post-treatment time points

Time-varying ATT
Averaged over time points
\[\begin{equation*} ATT \equiv \mathbb{E}\left[\overline{Y^1}_{\{t>T_0\}} - \overline{Y^0}_{\{t>T_0\}} \mid A = 1\right] \end{equation*}\]

Here, the overbar \(\overline{{\color{white} Y}}\) indicates averaging and the subscript \(_{\{t>T_0\}}\) refers to the time points over which the outcome is averaged.

The above estimands make sense when the treatment is administered at the same time for all treated groups. When treatment timing differences occur, Athey and Imbens (2018) and Goodman-Bacon (2018) discuss the weighted estimands that arise. We discuss diff-in-diff when there is variation in treatment timing briefly in the estimation section.

极光官网加速器官网

What kind of assumptions do we need to estimate the ATTs above? We consider several counterfactual assumptions that may require:

1. parallel latern破解版 专业版 outcomes in pre- to post-intervention periods
   
2. parallel outcome trends across certain time points, or
   
3. parallel outcome trends across all time points.

First, consider an assumption that average over the pre- and post-intervention time points, effectively collapsing back to the simple two-period case.

Counterfactual Assumption (2a)
Avg pre, avg post
\[\begin{align*} \mathbb{E} \left[\overline{Y^0}_{\{t > T_0\}} - \overline{Y^0}_{\{t \leq T_0\}} \mid A = 0\right] = \\ \mathbb{E} \left[\overline{Y^0}_{\{t > T_0\}} - \overline{Y^0}_{\{t \leq T_0\}} \mid A = 1\right] \end{align*}\]

Here, we assume that the difference between the average of the pre-intervention outcomes and the average of the untreated post-intervention outcomes is the same for both treated and control groups. To identify the latern破解版 专业版 ATT using this assumption, we use the same identification process as in the simple case with only one observation in each of the pre- and post-intervention periods.

Counterfactual Assumption (2b)
One pre, one post
For some \(t^* > T_0\), there exists a \(t' \leq T_0\) such that \[\begin{align*} \mathbb{E}\left[Y^0(t^*) - Y^0(t') \mid A = 1\right] = \\ \mathbb{E}\left[Y^0(t^*) - Y^0(t') \mid A = 0\right] \end{align*}\]

Counterfactual Assumption (2b) is a restriction on the data at two time points, one before and one after treatment. In a sense, time points other than these two are not relevant. Or at least, the other time points need not satisfy the “parallel trends” assumption. While this assumption is perfectly valid if true, using such an assumption requires justification. For instance, why do we believe this assumption is satisfied for two time points but not the rest? To identify the ATT using this assumption, we again use the same identification process as in the simple case, since we are back to considering only one time point pre-intervantion and one time point post-intervention.

Counterfactual Assumption (2c)
Lantern专业版apk
For some post-treatment time point landeng官网专业破解版, \[\begin{align*} \mathbb{E}\left[Y^0(t^*) - \overline{Y^0}_{\{t \leq T_0\}} \mid A = 0\right] = \\ \mathbb{E}\left[Y^0(t^*) - \overline{Y^0}_{\{t \leq T_0\}} \mid A = 1\right] \end{align*}\]

In this version we assume that there are “parallel trends” between one post-intervention time point and the average of the pre-intervention outcomes.

Counterfactual Assumption (2d)
All pre, one post
For some \(t^* > T_0\) and each \(t' \leq T_0\): \[\begin{align*} \mathbb{E}\left[Y^0(t^*) - Y^0(t') \mid A = 1\right] = \\ \mathbb{E}\left[Y^0(t^*) - Y^0(t') \mid A = 0\right] \end{align*}\]

Counterfactual Assumption (2d) is a stricter version of (2c), where parallel trends holds at post-intervention time \(t^*\) and every possible pre-intervention time point. Note that if Counterfactual Assumption (2d) holds, then Counterfactual Assumption (2c) also must hold, but the reverse is not necessarily true.

Counterfactual Assumption (2e)
All pre, all post
For each \(t^* > T_0\) and each \(t' \leq T_0\): \[\begin{align*} \mathbb{E}\left[Y^0(t^*) - Y^0(t') \mid A = 1\right] = \\ \mathbb{E}\left[Y^0(t^*) - Y^0(t') \mid A = 0\right] \end{align*}\]

This is the most restrictive because it requires parallel evolution of the untreated outcomes at all pre- and post-intervention time points.

landeng破解版安卓版2022

Provided there are enough time points, researchers often test whether trends are parallel in the pre-intervention period. But the test of parallel trends is neither necessary nor sufficient to establish validity of diff-in-diff (Kahn-Lang and Lang lan 灯 破解版). Moreover, conditioning a test of the diff-in-diff effect on “passing” a test for parallel pre-period trends changes the performance of the whole procedure (Roth 2018).

Recognizing that editors, reviewers, and readers may still want to see tests of parallel trends despite our recommendation against it, one possible work-around is to reformulate the test using a different null hypothesis, namely one designed to show “equivalence” of the pre-period trends (Hartman and Hidalgo 2018). Other possibilities include procedures that re-formulate the model to allow for non-parallel pre-period trends and focus on how this impacts treatment effect estimates (Bilinski and Hatfield 2018; Rambachan and Roth landeng官网专业破解版). In addition, robustness checks such as pre-period placebo intervention tests can assess the sensitivity of the conclusions to pre-period trend differences. For an excellent review of parallel trends testing in diff-in-diff, see McKenzie’s World Bank blog post.

landeng破解版安卓

Our primary concern with (the usual) hypothesis tests of parallel trends (one in which the null hypothesis asserts parallel trends) is that we can never actually prove what we set out to prove. The only conclusions that emerge from a conventional hypothesis test are “fail to reject the null” or “reject the null.” The decision to “fail to reject” is decidedly different than accepting the null. And in tests for parallel trends, the null is typically that the trends are parallel. So we can never actually say that our trends are parallel using the default infrastructure. Maybe this is a problem for some and perhaps not for others. However, there is another problem with hypotheses for testing assumptions. Let’s delve briefly into a thought experiment where the “parallelness” of trends is captured by a single parameter \(\theta\) (where \(\theta = 0\) denotes two lines that are perfectly parallel). Deviations from zero (either negative or positive) denote departures from “parallelness” at varying magnitudes. The hypotheses for testing parallel trends look something like:

latern专业破解版安卓最新版 \(\theta = 0\)

\(H_1:\) \(\theta \neq 0\).

If we have a big enough sample size we can reject the null if the true value of landeng破解版安卓 is 5 or 3 or 1 or 0.01. But do we really care about deviations of magnitude 0.01 compared to deviations of 5? It would be better if we could insert expert knowledge into this test and incorporate some margin for deviation in our test. Equivalence tests do just this, while at the same time reversing the order of the hypotheses. Let Lantern专业版apk denote an acceptable margin for deviations from parallel trends so that if \(|\theta| \leq \tau\), we feel OK saying that the trends are parallel (or close enough). The hypotheses for an equivalence test could be something like:

\(H_0:\) \(|\theta| > \tau\)

landeng破解版安卓版 \(|\theta| \leq \tau\).

Equivalence tests are nothing new. They are sometimes used in clinical trials to determine if a new drug is no worse than a standard-of-care drug, for example. They also happen to provide an intuitive approach to testing for parallel trends in the pre-treatment periods. Unfortunately, this setup won’t solve all our (diff-in-diff) problems. Sample size considerations can be a hindrance in assumption testing, for one. However, this sort of issue arises no matter how we construct our testing framework, so we might as well set up our tests in a way that is more intuitive.

极光官网加速器官网

In an upcoming section, we will explicitly show the effect that a confounder has on the parallel trends assumption. Nevertheless, we begin our discussion of confounding in diff-in-diff by highlighting an important distinction: time-invariant and time-varying. When we have a covariate that satisfies certain properties (associated with treatment group and with outcome trends), parallel trends will not hold. As the name suggests, a time-invariant confounder is unaffected by time. It is typically measured prior to administering treatment and remains unaffected by treatment and other external factors.

Another, more pernicious, type of confounder is the time-varying confounder. Time-varying covariates freely change throughout the study. Examples of time-varying covariates seen in observational studies are concomitant medication use and occupational status. Time-varying covariates are particularly troublesome when they predict treatment status and then are subsequently affected by treatment, which in turn affects their treatment status at the next time point. In effect, time-varying confounders act as both a confounder and a mediator. However, recall that treatment status in diff-in-diff is monotonic: the comparison group is always untreated, and the treated group only switches once, from untreated to treated.

With these treatment patterns in mind, let’s talk a bit about time-varying confounders. We need to assess whether the time-varying covariates are affected by treatment or not. In most cases, we cannot know for certain. For example, in a study assessing the effect of Medicaid expansion on hospital reimbursements, we can be fairly certain that the expansion affected insurance coverage in the population. On the other hand, factors such as the average age of the population might change from pre- to post-expansion. How much would Medicaid expansion have affected that change? If the validity of our diff-in-diff model relied on adjusting for these factors, we would have to account for these covariates in some way. Our next section will talk about estimation in diff-in-diff studies, including how to deal with confounding.

Fixed effects in diff-in-diff

Let’s talk about fixed effects briefly (see Mummolo and Peterson (2018) for a more in-depth discussion of fixed effects models and their interpretation). Fixed effects, particularly unit-level fixed effects, are used in causal inference to adjust for unmeasured time-invariant confounders. Of course, there are trade-offs. The discussion from Imai and Kim (n.d.) explains that using unit fixed effects comes at the cost of capturing the dynamic relationship between the treatment and the outcome.

Kropko and Kubinec (2018) discuss the common two-way fixed effects model, which includes unit and time fixed effects. Their main point is that estimates coming from two-way fixed effect models are difficult to interpret when we have many time periods. When we have the canonical (two-period, binary treatment) diff-in-diff setup, the \(\beta\) coefficient from the two-way fixed effect model \(\left(y_{it} = \alpha_i + \delta_t + \beta D_{it} + \epsilon_{it}\right)\) equals the usual estimate. As more time periods are added within the fixed-effects framework, we implicitly add supplementary assumptions. In particular, the diff-in-diff effect is assumed homogenous across time and cases. Homogeneity across time is a stringent assumption that says the diff-in-diff effect is the same no matter how close or far apart the time periods are. We say this not to discourage use of two-way fixed effect models, but to discourage automatic use of them. True they work well for some cases (when we need to adjust for unmeasured time-invariant confounders), but we really need to examine our research goals on an application-by-application basis, consider the assumptions implicit in the models we’re thinking of using, and adjust our tools accordingly.

What if treated units are treated at different times? Or what if we don’tcontrol group, only variation in treatment timing? Goodman-Bacon (2018) examines the two-way fixed effect regression model \((Y_i(t) = \alpha_i + \delta_t + \beta D_{it} + \epsilon_{it})\) as a diff-in-diff estimator when there exists treatment variation. It turns out that the diff-in-diff parameter \(\beta\) is a weighted combination of all possible \(2 \times 2\) diff-in-diff estimators found in the data. So each treatment group can be compared to the untreated group (if one exists), but each treatment group also serves as a control to every other treatment group. The global diff-in-diff estimate is a weighted average of all possible \(2 \times 2\) estimates. The weights are determined by sample sizes in each group and the variance in the treatment variable.

Bai (2009) describes an interactive fixed effects model that incorporates time-varying dynamics. Each unit is assumed to have an \(r\)-vector of factor loadings, \(\mathbf{\lambda}_i\), multiplies an lan 灯 破解版-vector of common factors at each time point \(\mathbf{F}_{t}\). That is, for outcome \(Y_{it}\) of unit \(i\) at time \(t\), the data-generating model is \[ Y_{it} = X_{it}'\beta + \lambda_{i1}F_{1t} + \ldots + \lambda_{ir}F_{rt} + \epsilon_{it}\;, \] where lan 灯 破解版 are observed covariates. Note that the two-way fixed effects model is a special case of this where lanter专业破解版百度云, \(F_{2t} = \delta_t\) and \(\lambda_{i1}= \alpha_{i}\), \(\lambda_{i2} = 1\). The authors present least-squares estimators for large \(N\) and large \(T\).

Marginal structural models can capture dynamics such as past outcomes affecting future treatments, but cannot account for time-invariant unmeasured confounders. Thus, we can either adjust for time-invariant unmeasured confounders and assume no dynamic relationship between treatment and outcome or we can assume that there are no unmeasured confounders and allow for more complicated relationships between treatment and outcome.

Confounding in linear settings

If we know how confounding arises, we can address it. For example, if the truth is a linear data-generating model, we can use a linear regression model to address confounding. The flowchart below outlines six linear data-generating models and the appropriate linear regression adjustment for each.

ios vpn中国:2021-10-11 · ios vpn中国 4伕i7 com.findtheway 2.2.6 鲨鱼一家 为什么热拉登录不了 网飞加速器怎么下载手机版 小明vp n翻墙 baavpn手机下载 狸猫vpm苹果怎么找不到 比特加速器手机破解版 苹果曝光软件 阿里云轻量服务器搭建ssr shadowrocks电脑版配置 ...

Time-invariant X with time-varying effect

In this scenario, the covariate \(X\) does not vary over time. The arrow from \(X\) to \(A\) indicates that \(X\) is a cause of \(A\), satifying the first requirement of a confounder. Additionally, are arrows from landeng破解版安卓版5.0.1 to \(Y(1)\) and to \(Y(2)\) as well as an arrow from \(A\) to \(Y(2)\). [Note: there is no arrow from landeng官网专业破解版 to \(Y(1)\) because treatment is administered after \(Y(1)\).] \(\alpha\) is the effect of \(X\) on \(Y(1)\), and \(\beta\) is the effect of \(X\) on \(Y(2)\). When \(\alpha = \beta\), the effect of \(X\) is time-invariant and we do not require covariate adjustment. When \(\alpha \neq \beta\), we must adjust for the interaction of \(X\) with time.

Time-varying X independent of treatment

In this scenario, the time-varying covariate landeng破解版安卓版2022 in periods 1 and 2 is denoted \(X(1)\) and \(X(2)\). There is no arrow connecting \(A\) to \(X(2)\), indicating that treatment does not affect the evolution of \(X(1)\) to landeng破解版安卓版. When landeng破解版安卓版2022, the effect of \(X\) is time-invariant and we do not need to adjust for the covariate. When \(\alpha \neq \beta\), we must adjust for the interaction of \(X\) with time.

Time-varying X related to treatment

In this scenario, the time-varying covariate \(X\) evolves differentially by treatment group. However, most diff-in-diff analyses implicitly or explicitly assume that \(X\) does not evolve based on treatment group. See our nonparametric section below. One diff-in-diff estimator that directly accounts for this phenomenon is Stuart et al. (2014), which we discuss in more detail below. When \(\alpha = \beta\), the effect of \(X_t\) on \(Y^0\) is time-invariant and it suffices to adjust only for \(X_t\). When latern专业破解版安卓最新版, we must adjust for the interaction of \(X_t\) with time.

Semi-parametric estimation with baseline covariates

Abadie (2005) addresses diff-in-diff when a pre-treatment covariate differs by treatment status and also affects the dynamics of the outcome variable. In our confounding section above, this is the “Time-invariant X with time-varying effect” scenario.

Let’s return to the two-period setting. When a covariate \(X\) is associated with both treatment \(A\) and changes in the outcome \(Y\), the Counterfactual Assumption 1 no longer holds.

Thus, Abadie (lanter 破解版) specifies an identifying assumption that conditions on \(X\). That is,

Conditional Counterfactual Assumption \[ \mathbb{E}\left[Y^0(2) - Y^0(1) \mid A = 1, X\right] = \mathbb{E}\left[Y^0(2) - Y^0(1) \mid A = 0, X\right]. \]

This assumption does not identify the ATT, but it can identify the CATT, that is, the conditional ATT:

Conditional average effect of treatment on the treated (CATT) Lantern 4.4.2 - 下载 - UpdateStar.com:Lantern, 免费下载. Team Lantern: Security 灯笼是一个用户友好和高效的软件创建, 众帮助您访问禁止网站, 绕过各种区域限制, 并增加您的匿名级别, 通过更改您的 IP 地址时, 浏览互联网。

The CATT itself may be of interest, or we may want to average the CATT over the distribution of lan灯破解版安卓版 to get back the ATT. To identify the CATT, repeat the identification steps above with expectations conditional on \(X\). As expected, it turns out that

\[\begin{align*} \mathbb{E}\left[Y^1(2) - Y^0(2) \mid A = 1, X\right] &= \lbrace \mathbb{E}\left[Y(2) \mid A = 1, X\right] - \mathbb{E}\left[Y(1) \mid A = 1, X \right] \rbrace - \\ & \ \ \ \ \ \lbrace \mathbb{E}\left[Y(2) \mid A = 0, X\right] - \mathbb{E}\left[Y(1) \mid A = 0, X \right] \rbrace. \end{align*}\]

Nonparametric estimators for these quantities are easy when \(X\) is a single categorical variable. They are simply sample averages for groups defined by combinations of \(X\) and \(A\):

1. The post-treatment average of the treated group with \(X=x\) for \(\mathbb{E}\left[Y(2) \mid A = 1, X=x\right]\)
   
2. The pre-treatment average of the treated group with \(X=x\) for \(\mathbb{E}\left[Y(1) \mid A = 1, X=x\right]\)
   
3. The post-treatment average of the control group with \(X=x\) for \(\mathbb{E}\left[Y(2) \mid A = 0, X=x\right]\)
   
4. The pre-treatment average of the control group with \(X=x\) for \(\mathbb{E}\left[Y(1) \mid A = 0, X=x\right]\)

However, if \(X\) is high-dimensional or contains continuous covariates, these get tricky. Abadie proposes a semiparametric solution using propensity scores. Recall that a propensity score is the estiamted probability of treatment given pre-treatement covariate \(X\), \(P(A = 1 \mid X)\). For this approach to work, we need to use the positivity assumption, which was introduced in the assumption section. That is,

Positivity Assumption \[\begin{equation*} 0 < P(A = 1 | X) < 1 \; \text{ for all } X. \end{equation*}\]

This assumption ensures the estimand is defined at all \(X\). If some values of \(X\) lead to guaranteed treatment or control (i.e., propensity scores of \(0\) or \(1\)) we should reconsider the study population.

With positivity in hand, consider the weighted estimator of Abadie (2005):

\[\begin{equation} \mathbb{E}\left[Y^1(2) - Y^0(2) \mid A = 1\right] = \mathbb{E}\left[\frac{Y(2) - Y(1)}{P(A = 1)} \cdot \frac{A - P(A = 1 \mid X)}{1 - P(A = 1 \mid X)}\right]. \end{equation}\]

To estimate these quantities, we need fitted values of the propensity scores for each unit, i.e., \(\hat{P}(A=1 | X= x_i)\) and then we use sample averages in the treated and control groups. To see the math,

We only need the average change in outcomes among the treated units and the lan 灯 破解版 average change in outcomes among the control units. The weights are \(\frac{\hat{P}(A=1 | X=x_i)}{1 - \hat{P}(A=1 | X=x_i)}\). What are these weights sensible? Well, outcome changes among control units with \(x_i\) that resemble treated units (i.e., with large \(\hat{P}(A=1 | X=x_i)\)) will get more weight. Outcome changes among control units with \(x_i\) that resemble control units will get less weight.

To model the propensity scores, we could use a parametric model like logistic regression or something more flexible like machine learning. As usual, extending the model to multiple time points in the pre- and post-treatment periods is more complicated.

landeng破解版安卓版2022

Athey and Imbens (latern破解版 专业版) developed a generalization of diff-in-diff called “changes-in-changes” (of which diff-in-diff is a special case). This method drops many of the parametric assumptions of diff-in-diff and allows both time and treatment effects to vary across individuals. Again we are in a two-period, two-group setting. The Athey and Imbens (2006) model is much less restrictive than the usual parametric model. It only assumes two things:

1. \(Y_i^0 = h(u_i, t)\) for unobservable characteristics \(u_i\) and an unknown function \(h\) (increasing in \(u\))
2. Within groups, the distribution of landeng破解版安卓版最新 does not change over time

Note that the distribution of \(u_i\) can differ between treatment groups so long as this difference remains constant. Below, we discuss a method for estimating diff-in-diff without this assumption. To estimate the target parameter, Athey and Imbens (2006) estimate empirical outcome distributions in a familiar list of samples:

1. The post-treatment distribution of \(Y\) in the treated group,
   
2. The pre-treatment distribution of \(Y\) in the treated group,
   
3. The post-treatment distribution of \(Y\) in the control group, and
   
4. The pre-treatment distribution of \(Y\) in the control group.

What we are missing is

5. The post-treatment distribution of lan 灯 破解版 in the treated group (i.e., counterfactual, untreated outcomes)

Since we cannot observe this distribution, Athey and Imbens (2006) estimate it through a combination of the empirical distributions for (1), (2), and (3). After estimating (5), the effect of treatment is the difference between observed (4) and estimated (5). Let latern破解版 专业版 be the counterfactual distribution for the untreated outcomes for the treated group at \(t = 2\). We estimate this quantity through the relation:

tunnellight安卓版__tunnellight安卓版_最新资讯:2021-4-24 · landeng破解版安卓版 vpm下载安卓破解版 非凡vnp手机版 tunnellight安卓 怎么下载tunnellight tunnellight 下载 tunnel 网友正在搜 i7一7500u比较i5一8625u hololive aki是谁 一夫当关的最后决战 asta asta nahxa 危国永 张爽 chinese bear 11 多亲1s安装qq 许昌尚集镇 ... where \(F_{Y_{11}}\) is the distribution function for the (observed) outcomes for the treated group at \(t = 1\); \(F_{Y_{01}}\) is the distribution function for the (observed) outcomes for the untreated group at \(t = 1\); and \(F_{Y_{02}}\) is the distribution function for the (observed) outcomes for the untreated group at \(t = 2\).

The other distribution of note, latern破解版 专业版, is actually observed since this are the treated outcomes for the treated group at \(t = 2\). Since we have estimates for both \(F_{Y^1_{12}}\) and \(F_{Y^0_{12}}\), we can also estimate the diff-in-diff effect. MATLAB code for this estimator is available on the author’s website.

Bonhomme and Sauder (2011) extend this idea to allow the shape of the outcome distributions to differ in the pre- and post-intervention periods. The cost of this additional flexibility is that they must assume additivity.

latern破解版 专业版

One of the key identifying assumptions from Athey and Imbens (2006) is that the distribution of \(u\) — all non-treatment and non-time factors — is invariant across time within the treated and control groups. That is, the distributions do not change with time. Stuart et al. (2014) circumvents this restriction by considering four distinct groups (control/pre-treament, control/post-treatment, treated/pre-treatment, treated/post-treatment) rather than just two groups (control and treated) observed in two time periods. With the four groups, the distribution of \(u\) can change over time. A consequence of this setup is that it no longer makes sense to talk about the diff-in-diff parameter as the effect of treatment on the treated; instead, the estimand is defined as the effect of treatment on treated in pre-treatment period.

The estimator uses propensity scores for predicting the probabilities of each observation being in each of the four groups. We can use some kind of multinomial regression. The treatment effect is then calculated as a weighted average of the observed outcomes (see section 2.4 of Stuart et al. (2014)).

Collapsing the data

Collapsing or aggregating again returns us to the simple two-period setting, obviating the need to consider longitudinal correlation in the data. When treatment is administered at the same time point, we can perform ordinary least squares on the aggregated data. On the other hand when treatment laws are staggered (e.g., states pass the same health care law in different years), Bertrand, Duflo, and Mullainathan (2004) suggests aggregating the residuals from a regression model and then analyzing those. See Goodman-Bacon (Lantern专业版apk) and Athey and Imbens (2018) for more about varying treatment start times.

In simulation studies, Bertrand, Duflo, and Mullainathan (2004) and Rokicki et al. (2018) find that aggregation has good Type I error and coverage, but it does lose some information (and thus power).

lan 灯 破解版

The most popular way to account for serial correlation in diff-in-diff is clustered standard errors (Cameron and Miller 2015; Abadie et al. 2017). In practice, this is typically done in Stata using the cluster option from the Lantern专业版apk function. Similar adjustment is available in any common statistical software. We declare which variable or variables constitute our clusters, and the software makes some kind of adjustment to the standard standard errors by accounting for within-cluster correlation.

This type of adjustment fails with only one treated unit (Conley and Taber 2011), for example, when a single state implements a policy of interest. There is no hard and fast rule on the number of treated units needed for clustered standard errors to be appropriate. Generally, it is better to have a balanced treated-control ratio than a lopsided one. As we mentioned in the preface to this section, Rokicki et al. (2018) examined DID inference when there were few groups. In particular, see Figures 2 (panel A) and 4 in that paper. Figure 2 examines 95% confidence interval coverage for the DID parameter under various inference techniques. In panel A, we can see that when the number of groups is small, clustering standard errors results in undercoverage, and this undercoverage is worse when the treated-to-control ratio is unbalanced. In Figure 4, coverage is presented as a proportion of the treated units to the control units. Whenever there is an unbalanced proportion of treated to control units, coverage suffers.

Fortunately, other choices exist if clustered standard errors are untenable and may even be preferred in many situations. Donald and Lang (Lantern专业版apk) developed a two-part procedure for estimation and inference in simple models that works well even when the numbers of groups is small.

Mixed models with random effects at the cluster level can account for serial correlation. This is what we used in our demonstration of confounding in a previous section. Generalized estimating equations (GEE) take into account covariance structure and use a robust sandwich estimator for the standard errors (see Figure 2, panel D and Figure 4 in Rokicki et al. (2018)). Both of these methods are widely available in statistical software. In particular, GEE is powerful since it is robust to the misspecification of the correlation structure so if we guess incorrectly, it will not bias our estimate when the underlying regression model is correct. Specifying the correct covariance will increase the efficiency of our estimate. However, note that Rokicki et al. (2018) also found undercoverage in the confidence interval in the GEE estimates when the ratio of treated to control units was lopsided.

Arbitrary covariance structures

Throughout the diff-in-diff literature, we find simulations and inference techniques based on an autoregressive covariance AR(1) structure for the residuals within a cluster. The AR(1) covariance structure is

\[ \text{Cov}(Y_i) = \sigma^2 \begin{pmatrix} 1 & \rho & \rho^2 & \cdots & \rho^{n-1} \\ \rho & 1 & \rho & \cdots & \rho^{n-2} \\ \rho^2 & \rho & 1 & \cdots & \rho^{n-3}\\ \vdots & \vdots & \vdots & \ddots & \vdots \\ \rho^{n-1} & \rho^{n-2} & \rho^{n-3} & \cdots & 1 \end{pmatrix} \]

with an unknown variance parameter \(\sigma^2\) and an unknown autoregressive parameter \(0 \leq \rho \leq 1\). When \(\rho\) is larger, clustered values are more highly correlated; whereas when \(\rho = 0\), observations are independent. This structure assumes that correlation is positive (or zero) across all observations and that observations closer to each other are the most strongly correlated, and observations that are more distant are more weakly correlated.

The AR(1) correlation structure is pervasive in diff-in-diff simulation studies and inference techniques. Bertrand, Duflo, and Mullainathan (2004) considered this correlation structure in simulations and found that “this technique [assuming AR(1)] does little to solve the serial correlation problem” due to the difficulty in estimating \(\rho\). Rokicki et al. (2018) used an AR(1) in their simulations.

McKenzie (2012) also discusses autocorrelation, emphasizing how statistical power relates to the number of time points and to autocorrelation, ultimately concluding that ANCOVA is more powerful than diff-in-diff.

The correlation structure in diff-in-diff applications may follow many different structures. For example, after de-meaning and de-trending, outcomes have a weak positive correlation in adjacent time points but a negative correlation at time points in far apart time points. In the shiny app below, we present correlation structures for simulated data and real data. The real datasets are from (a) the Dartmouth Health Atlas, (b) MarketScan claims data, and (c) Medicare claims, which are described in more detail within the app. Play around with the settings to simulate data that look like your applications. Does the correlation structure look the way you expect?

Permutation tests

Permutation tests are a resampling method that can be used to test statistical hypotheses. In the diff-in-diff setting, permutation tests comprise the following steps:

1. Compute the test statistic of interest on the original data. For example, calculate the interaction term between time and treatment from a regression model. Call this \(\hat{\delta}\).

2. For \(K\) a large positive integer, permute the treatment assignment randomly to the original data, so that the data are the same save for a new treatment assignment. Do this \(K\) times.

3. For each of the \(K\) new datasets, compute the same test statistic. In our example, we compute a new interaction term from a regression model. Call these \(\hat{\delta}^{(k)}\) for permutation \(k \in \{1, \dots, K\}\).

4. Compare the test statistic \(\hat{\delta}\) found in the first step to the test statistics \(\hat{\delta}^{(1)}, \dots, \hat{\delta}^{(K)}\) found in the third step.

The fourth step is where we can get a nonparametric p-value for the parameter of interest. If, for instance, lan 灯 破解版 is more extreme than 95% of \(\hat{\delta}^{(k)}\) then the permutation test p-value is 0.05.

For more on randomization inference for difference-in-differences, see Conley and Taber (2011) and MacKinnon and Webb (2018).

lanter 破解版

Lechner and others (2011) perform a thought experiment that we summarize here. Imagine we are doing a data analysis using diff-in-diff, and that our data have are multiple pre-treatment time points. Now, imagine we artficially move the treatment time to one of those earlier time points (i.e., prior to the time that the treatment was actually received). If we were to conduct a diff-in-diff analysis, what would your expecations be for the estimate of the treatment effect?

In an ideal world, the treatment effect would be null.

Instrumental Variable Approach For Diverging Trends

Freyaldenhoven, Hansen, and Shapiro (2018) propose an approach to address the issue of diverging parallel trends due to an unobserved confounder. Their approach identifies an observed covariate that serves as an instrument for the unobserved confounder. They assume there is a latent variable that triggers treatment once it passes a threshold. For example, once a person’s income falls below a particular threshold, she becomes eligible for food stamps. They show that if we can identify a covariate that is related to income but unrelated to the food stamp intervention, we can use 2-stage least squares to estimate an unbiased treatment effect. This method is appealing both because it provides a mechanism to address bias and encourages researchers to think explicitly about unobserved confounders and their role in inducing bias. However, this framework relies heavily on being able to identify and find an instrument for unobserved confounders, which may be difficult to do in practice.

Synthetic Difference-in-Differences

Arkhangelsky et al. (2024) propose an extension to SCM called Synthetic Difference-in-Differences (SDID), which combines elements of both DID and SCM. Most DIDs incorporate both unit and time fixed effects, which weights each comparison unit and each time period equally. SCM incorporate unit-level weights and time fixed effects. SDID adds additional flexibility by incorporating all of these elements: 1) unit and time fixed effects and 2) unit- and time-level weights.

\[ \hat{\omega}^{sc} = \underset{\omega \in W}{\text{arg min}} \sum^{T-1}_{t = 1} \left(\sum^{N-1}_{i=1} \omega_iY_i(t) - Y_N(t)\right)^2 \]

\[ \hat{\lambda}^{sc} = \underset{\lambda \in L}{\text{arg min}} \sum^{N-1}_{i = 1} \left(\sum^{T-1}_{t=1} \lambda_iY_i(t) - Y_i(T)\right)^2 \]

\[ \left(\hat{\theta}^{sdid}, \hat{\tau}^{sdid}\right) = \underset{\theta}{\text{arg min}} \sum^N_{i=1}\sum^T_{t=1}\left( Y_i(t) - g(\theta)_{it} - \tau W_{it}\right)^2\hat{\omega}_i\hat{\lambda}_t \]

The authors demonstrate that this approach is doubly-robust: as \(N\) and landeng破解版安卓版最新 go to infinity, the SDID estimators is consistent if either 1) the unit and time weights or 2) the outcome model are correctly specified. (This roughly corresponds to either SCM with additional weight flexibility or DID being consistently estimated.)

Augmented Synthetic Control

Augmented SCM (ASCM) is another extension of synthetic controls. Ben-Michael, Feller, and Rothstein (landeng破解版安卓版5.0.1) select weights to minimize the difference in pre-intervention level then subtract an estimate of the remaining level difference from the post-intervention difference. This addresses the “curse of dimensionality”: while SCM is unbiased as the number of pre-intervention time periods grows, researchers are less likely to identify a good fit as the number of time periods grows, even when one exists, unless they have a very large number of control units. Both ASCM and SDID methods can weight up recent periods relative to distant periods when estimating this level difference. Further, both ASCM and SDID involve a correction to the SCM estimator that is 0 if there is exact pre-intervention balance. These methods only apply when there is imperfect pre-intervention balance and matter most when there is substantial pre-intervention imbalance.

Generalized Synthetic Control

Xu (2017) proposed the generalized synthetic control method, which combines an interactive fixed effects model with the framework of synthetic control. The basic idea is to use a parametric factor model for the outcomes to predict the “missing” untreated potential outcomes for the comparison group. The factor model assumes that a small set of time-varying factors interact with unit-specific “factor loadings” to generate the outcome. Note that the popular two-way fixed effects model (with unit and time fixed effect) is a special case of a factor model.

Within the generalized synthetic control framework, Xu (2017) writes the outcome for unit \(i\) at time \(t\) as

\[ Y_i(t) = \delta_{it}D_{it} + x_{it}\beta + \lambda_i f_t + \epsilon_{it}, \] ] where \(D_{it}\) is a treatment indicator which equals 1 whenever the unit \(i\) receives treatment at time \(t\), \(\delta_{it}\) are heterogeneous effects, \(x_{it}\) and \(\beta\) are covariates and their coefficients, and \(\lambda_i\) and \(f_t\) are factor loadings and factors, respectively.

To use the generalized synthetic control method, we first estimate the latent factors, \(f_t\), and the coefficients on the covariates, \(\beta\), using only the data from the control units (with least squares and some additional restrictions like orthogonality of the factors, for one). Then we estimate the factor loadings of each treated unit, \(lambda_i\), by minimizing a least squares equation for the treated units’ outcomes in the pre-treatment period, conditional on the factors and coefficients estimated in the first step. Finally, we use the estimated coefficients, factors, and factor loadings in the parametric outcome model to predict counterfactual untreated outcomes in the post-treatment period for the treated units:

\[ \hat{Y}^0_i(t) = x_{it}\hat{\beta} + \hat{\lambda}\hat{f_t}. \]

Following this step, the ATT is simply the average (within the treated group only) of the observed post-treatment outcomes minus the predicted untreated outcomes:

\[ ATT(t) = \frac{1}{N_t} \sum_i Y_i(t) - \hat{Y}^0_i(t), \] where the summation iterates over all treated units and \(N_t\) denotes the number of treated units.

The strengths of the method are that the factor structure can address time-varying confounding (unlike diff-in-diff); it incorporates heterogeneous treatment effects (unlike interactive fixed effects); and it can accommodate multiple treated units, observed covariates, and treated units outside the convex hull of the controls (unlike the synthetic control formulation of Abadie, Diamond, and Hainmueller (2010)). The limitations of this method include the requirement for a reasonably long pre-treatment period, the reliance on a parametric model for the outcome, and the lack of obvious safeguards against inappropriate controls (i.e., those that lack common support with the treated units).